Analytics Evolution from Decision Tree to GenAI
How do analytics professionals explain AI / ML to the non-technical user community? How far have we traveled in the past few decades from a Decision Tree tool to Generative AI? As a veteran in this space, I studied economics in college and programmed in SAS, a statistical modeling tool. My colleagues in the 1990s…
Have a Try: Tracing a Career Through Curiosity, Creativity, and Purpose
Many of us across our #Linkedin community ask how we get where we are now #career-wise. Thanks to #NYC, the city that never sleeps, I have met many of you who have shared your unique stories. There were three pivotal moments that have shaped my experience and vision. Each event, though seemingly senate, has…
Reflection: an End-of-Year Message from an AIPurpose Co-Founder
As the Co-Founder of AI4Purpose Inc. (https://ai4purpose.com), a nonprofit organization based in New York City (NYC), I would like to say a warm welcome and celebration, which marks the end of our founding year of 2024. It was a whirlwind of establishing AI4Purpose Inc., to innovate, connect and mentor in artificial intelligence (AI) and related…
IMPACCT RWE Summit Allows Exploration of Future of Real-World Evidence
1,049 words, 6 minutes read time. Kelly H. Zou Kelly H. Zou, Ph.D., PStat® is Founder and CEO, AI4Purpose Inc. and Head of Global Medical Analytics, Real World Evidence, and Health Economics and Outcomes Research, Viatris Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously at Pfizer Inc, she…
Empowering Healthcare with Real-World Data and Artificial Intelligence: Ensuring Responsible Use and Exploring Key Use Cases
975 words, 5 minutes read time. Seray Cicek Seray Cicek holds a MSc in Pharmaceutical Sciences and BASc in Engineering Science (Biomedical) from the University of Toronto. Her graduate studies at Keith Pardee’s lab focused on development of a low-cost diagnostic device for the detection of Zika virus in patient samples, and deployment of these…
From Randomized Trials to Real-World Data: The Evolution of Outcomes Research and the Path Forward
1,190 words, 6 minutes read time. Marc Berger Marc L. Berger, MD, is a semi-retired, part-time consultant and scientific advisor. Until July 2017, he was Vice President, Real World Data and Analytics at Pfizer, Inc. Marc has held senior-level positions in industry including Executive Vice President and Senior Scientist at OptumInsight; Vice President, Global Health…
